Evidence Profile — RWE & HEOR, Oncology & Specialty Care

Pavani MallaPharmD

RWE & HEOR Leader — Oncology & Specialty Care

I generate payer-, regulatory-, and publication-ready real-world evidence across oncology and specialty care — turning claims and EHR data into evidence that informs access, reimbursement, and clinical decisions.

Vancouver, Washington, United States pavanimalla@yahoo.com LinkedIn ↗ Google Scholar ↗
Get in touch →
10+
Years in oncology research, managed care analytics & HEOR
8
Health systems, payers & academic partners
5
Publications & research contributions
3
Degrees — PharmD, M.S., B.S.
About

Evidence that holds up — for payers, regulators, and clinicians

With over a decade of experience spanning oncology research, managed care analytics, and health economics and outcomes research (HEOR), I support organizations in designing and executing observational studies, comparative effectiveness analyses, economic models, and evidence strategies that inform access, reimbursement, and clinical decision-making.

My work includes claims- and EHR-based observational RWE studies, comparative effectiveness and external control arm analyses, budget impact and cost-effectiveness modeling, payer-facing value narratives and AMCP-style evidence packages, and publication-ready analytics and scientific manuscripts.

I combine rigorous analytical execution with strategic evidence positioning — ensuring that data is not only methodologically sound, but decision-ready for medical affairs, market access, and payer stakeholders.

I selectively collaborate on RWE and HEOR engagements where senior-level analytical and strategic support is required.

Therapeutic Areas
  • Oncology
  • Hemophilia
  • Migraine
  • Opioid Care
  • Immune-Mediated Disease
Top Skills

Where I focus

EVIDENCE STRATEGY

Strategy

Designing evidence generation plans — from study concept through publication — that align with regulatory, clinical, and commercial objectives.

PAYER STRATEGY

Market Access

Building payer-facing value narratives, AMCP-style evidence packages, and formulary positioning that connect data to reimbursement decisions.

CROSS-FUNCTIONAL

Medical Affairs

Partnering across medical affairs, market access, and RWE centers of excellence to turn analysis into decisions stakeholders can act on.

Experience

An evidence record, by era

A career arc from translational bench research into enterprise RWE & HEOR leadership. Each entry is tagged by study design or therapeutic focus.

RWE & HEOR Leadership — 2020 to Present

April 2025 – Present

Sr. Clinical Informatician & Program Manager — Population Health and Clinical Outcomes

Centene Corporation · St. Louis, Missouri

PROGRAM LEADERSHIP

Leads multidisciplinary teams across clinical research, health economics, and data science to advance evidence generation and market access strategy across a broad therapeutic portfolio, partnering with medical affairs, market access, and RWE centers of excellence.

  • Serves as HEOR & RWE subject-matter expert, integrating economic models and value evidence into payer and commercialization strategy.
  • Builds cost-effectiveness, budget-impact, and ROI models supporting pricing, reimbursement, and policy decisions.
  • Uses SQL, SAS, R, Tableau, and Power BI to develop dashboards tracking cost, quality, and performance (HEDIS, STARs, RAF).
January 2021 – November 2024

Clinical Data & Research Project Manager — HEOR and RWE Analytics

Oregon Health & Science University · Portland, Oregon

RWE & HEOR ANALYTICS

Managed three multi-center retrospective and prospective oncology studies — designing EDC workflows, leading statistical modeling, and producing regulatory-compliant deliverables and conference presentations.

Tacrolimus Levels & Outcomes After Allogeneic Stem Cell Transplant

RETROSPECTIVE COHORT

with UC San Diego Health – Moores Cancer Center

Logistic regression and Kaplan-Meier modeling of tacrolimus dosing strategy and acute graft-versus-host disease risk.

Cannabis Product Use by Oncology Patients

PROSPECTIVE OBSERVATIONAL

Patient interviews and EMR analysis informing oncology symptom-management protocols for nausea, pain, and appetite.

Risk Factors for Mucositis Under Methotrexate Therapy

CASE-CONTROL · N=600+

with Baylor Scott & White Health

CDISC SDTM/ADaM-compliant modeling of mucositis predictors in graft-versus-host-disease populations.

July 2020 – June 2024

Senior Healthcare Data Informaticist — RWE & HEOR (Clinical Analytics)

Moda Health · Portland, Oregon Metro Area

MANAGED CARE ANALYTICS

Led RWE and HEOR initiatives across oncology, hemophilia, and opioid care, using medical and pharmacy claims and interoperability standards (HL7, FHIR, OMOP) to inform formulary and reimbursement strategy.

Access to Oncological Therapies & Care Management

ONCOLOGY

Modeled treatment-access disparities and the economic impact of biosimilars and immunotherapies.

Hemophilia Patient Care Cost Management

HEMOPHILIA

Evaluated cost-effectiveness of factor-replacement therapies and centralized access-to-care models.

Opioid Care Management & Overdose Outreach

OPIOID STEWARDSHIP

Built overdose-risk models and Tableau dashboards supporting medication-assisted treatment access.

May 2012 – December 2023

Freelance Medical Writing — Oncology, Rare Diseases, HEOR & RWE

Freelance — Self Employed

MEDICAL WRITING

Authored regulatory documents (CSRs, IBs, RMPs) and scientific manuscripts for oncology and rare-disease therapeutics, translating claims- and EHR-derived evidence into payer dossiers and HTA reports.

  • FDA, EMA, and ICH-GCP-compliant regulatory and briefing documents.
  • Adherence-focused HEOR publications on biologic therapies and oncology drug persistence.
  • RWD dashboards visualizing treatment adherence and formulary impact for payer stakeholders.
January 2020 – June 2020

Claims Data Analyst

Molina Healthcare · Santa Monica, California

CLAIMS ANALYTICS

Supported Pharmacy Department operations, building SQL and SSIS ETL pipelines across SQL Server, SAS, Access, and Oracle to support 340B program reporting and clinical decision data needs.

  • Built and tested SSIS packages to automate routine data processes.
  • Developed Tableau visualizations streaming from SQL Server, flat files, and Oracle databases.

Earlier — Translational & Bench Research, 2012–2019

February 2019 – December 2019

Senior Research Technologist — Data Integration & Visualization Specialist

Oregon Health & Science University · Portland, Oregon Metro Area

TRANSLATIONAL ONCOLOGY

Led biomarker and drug-efficacy research using single-cell imaging and high-content microscopy, integrating microscopy, flow cytometry, and EHR data to study drug-resistance mechanisms in leukemia and solid tumors.

February 2017 – January 2019

Research Associate — Oncology Drug Resistance, Precision Oncology & HEOR

OHSU Knight Cancer Institute · Portland, Oregon Metro Area

Ph+ ALL RESEARCH

Investigated Venetoclax resistance and kinase-inhibitor interactions in Philadelphia-chromosome-positive ALL — showing that dual ABL/Src kinase inhibitors blunt blinatumomab's T-cell-mediated efficacy.

June 2015 – February 2017

Cancer Research Associate — Breast & Prostate Cancer Epigenetic Pathways

Moffitt Cancer Center · Tampa/St. Petersburg, Florida

TNBC & CRPC RESEARCH

Studied therapeutic resistance in triple-negative breast and castration-resistant prostate cancer, including AR-reactivation pathways and TNK2/ACK1 as a novel TNBC target.

January 2015 – June 2015

Adjunct Faculty — General Chemistry

Southern Technical College · Tampa/St. Petersburg, Florida

TEACHING

Delivered chemistry theory and lab courses for nursing students, including curriculum development and lab-safety supervision.

May 2012 – December 2014

Graduate Research & Teaching Assistant

Texas A&M University–Commerce · Commerce, Texas

CATALYSIS RESEARCH

Researched palladium-gold bimetallic nanocatalysts for controlled acetylene hydrogenation in polyethylene production, while teaching general, inorganic, and biochemistry labs.

Publications & Research

Selected work

For the complete, current list of citations, see the Google Scholar profile.

Education

Academic background

Oregon State University
Doctor of Pharmacy (PharmD) · Pharmacy
September 2020 – December 2024
Texas A&M University–Commerce
Master of Science (M.S.) · Chemistry
2012 – 2014
Vignan Institute of Pharmaceutical Technology
Bachelor's Degree (B.S.) · Pharmaceutical Sciences
2007 – 2011

Let's talk evidence strategy

Open to selective RWE & HEOR engagements in oncology and specialty care.